YouTube Facebook LinkedIn Google+ Twitter Xingrss  

MyoKardia Gains Venture Funds to Investigate Drugs for Genetic Heart Defects

September 21, 2012 | Third Rock Ventures is investing $38 million in a startup that is targeting the genetic causes of heart problems. MyoKardia will set up shop in San Francisco, and will be led by Third Rock venture partner Charles Homcy and a team of top academic scientists who study the genetics of cardiovascular disease and muscle biology. Xconomy
View Next Related Story
CRISPR in the Germline | Mar 20, 2015
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 ,